<![CDATA[Rheumatoid arthritis (RA) leads to progressive functional impairment and considerable economic burden. This study estimated the annual (12-month) cost per patient among patients with RA and its determinant factors. A descriptive cross-sectional economic study of RA patients who had been treated for at least one year at the outpatient clinic of a national referral hospital in Jakarta, Indonesia, and met the 2010 ACR–EULAR criteria. Data collected from January 2023 to December 2024 were obtained from medical and billing records for demographic characteristics, direct medical costs, and DAS28-based disease activity, whereas non-medical and indirect costs were collected through structured patient interviews. Costs were viewed from a societal perspective, direct medical costs were calculated from hospital tariffs and expressed in 2023 USD. Associations between total cost and its determinant factors were examined using bivariate analyses and multivariable linear regression. Disease-modifying antirheumatic drug (DMARD) utilization was summarized by frequency and annual cost. A total of 150 RA patients were analyzed, predominantly female (94.7%), and all covered by the National Health Insurance (NHI). The mean annual total cost per patient was USD 790, driven mainly by direct medical costs (mean USD 591), particularly medicines (mean USD 337). Total cost was significantly associated with age (p = 0.02) and disease activity (p < 0.01), both remaining significant in multivariable analysis. Higher disease activity was consistent with more frequent combination DMARD. In conclusion, the annual outpatient cost of RA increased with older age and higher disease activity, with medicines being the primary cost driver.]]>
Copyrights © 2026
